Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that the Retail Offer announced on 26 March 2026 and which closed at 12.00 pm yesterday, has raised c.£274,000, before expenses.

Accordingly, subject to the passing of certain Resolutions at the forthcoming General Meeting (11.00 am on 13 April 2026), the Retail Offer will result in the issue of a total of 45,665,573 Retail Offer Shares at the Issue Price of 0.6p per share, to raise gross proceeds of approximately £274,000. As a result, the Company has raised a total of approximately £4.5 million pursuant to the Placing, Subscription and the Retail Offer, of which approximately £3.1 million remains conditional on the passing of certain Resolutions at the General Meeting.

Notice of General Meeting and posting of Circular

The Circular and notice of General Meeting are available on the Company’s website and were posted to shareholders on 27 March 2026.

Unless otherwise defined, definitions contained in this Announcement have the same meaning as set out in the announcement made by the Company on 25 March 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the...

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million...

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset...

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd...

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer®...

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer®...

    Search